Clincosm LogoSign in Get a demo

The Effects of Antibiotic Combinations on Stem Cells

Sponsor
Eskisehir Osmangazi University (Other)
Overall Status
Completed
CT.gov ID
NCT04713436
Collaborator
TC Erciyes University (Other)
3
Enrollment
1
Location
37
Actual Duration (Months)
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study was to evaluate the indirect effects of antibiotic combinations. SCAP viability, proliferation and apoptosis of the cells were evaluated. Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.

Condition or Disease Intervention/Treatment Phase
  • Drug: Differentiation Markers

Detailed Description

The purpose of this study was to evaluate the indirect effects of triple (TAP- ciprofloxacin, metronidazole and minocycline), double (DAP- ciprofloxacin and metronidazole) and modified triple antibiotic pastes (mTAP- ciprofloxacin, metronidazole and cefaclor) on mesenchmal stem cells derived from apical papilla (SCAP). SCAP were isolated from the impacted third molar teeth of the young adults. TAP, DAP and mTAP treatment (14-day medication and 28-day medication) were applied on SCAP and viability, proliferation and apoptosis of the cells were evaluated after four weeks. Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.

Study Design

Study Type:
Observational
Actual Enrollment :
3 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
The Effects of Antibiotic Combinations on Mesenchymal Stem Cells Derived From Apical Papilla
Actual Study Start Date :
Jan 1, 2014
Actual Primary Completion Date :
Jan 1, 2016
Actual Study Completion Date :
Feb 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Triple antibiotic paste(TAP)

ciprofloxacin, metronidazole and minocycline

Drug: Differentiation Markers
Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.
Other Names:
  • Gene expression levels

    		•
    Doble antibiotic paste(DAP)

    ciprofloxacin and metronidazole

    Drug: Differentiation Markers
    Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.
    Other Names:
  • Gene expression levels

    		•
    Modified triple antibiotic paste(mTAP)

    ciprofloxacin, metronidazole and cefaclor

    Drug: Differentiation Markers
    Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.
    Other Names:
  • Gene expression levels

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Measurment of Cell Viability and Apoptosis [1 year]

      To evaluate cell viability and apoptosis MuseCell Analyzer Count and Viability kit (Merck Millipore, Taufkirchen, Germany) was used according to the manufacturer's protocol.

    2. Measurment of cell differantiation [1 year]

      To determine gene expression levels, total RNA of SCAP was extracted using the Ambion PureLink RNA mini kit (Invitrogen, US) and the Roche cell RNA Kit (Penzberg, Germany) according to the manufacturer's instructions.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years to 22 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Patients with open apex third molar teeth for extraction indication
    Exclusion Criteria:
    • Patients with mature apex third molar teeth for extraction indication

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Eskişehir Osmangazi University Eskişehir Turkey 26040

    Sponsors and Collaborators

    • Eskisehir Osmangazi University
    • TC Erciyes University

    Investigators

    • Principal Investigator: Seçil Çalışkan, Eskişehir Osmangazi University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Seçil Çalışkan, Assistant Professor, Eskisehir Osmangazi University
    ClinicalTrials.gov Identifier:
    NCT04713436
    Other Study ID Numbers:
    • 2015-68
    First Posted:
    Jan 19, 2021
    Last Update Posted:
    Jan 19, 2021
    Last Verified:
    Jan 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Jan 19, 2021